MSD

Koneksa Announces Merck Joins Data Syndication Partnership Program Around Parkinson’s Digital Biomarkers Observational Study

Retrieved on: 
Mercoledì, Marzo 20, 2024
Mobile, Wireless, Hardware, Data Management, Biometrics, Consumer Electronics, Technology, Health Technology, Clinical Trials, Nanotechnology, Neurology, Biotechnology, Wearables, Mobile Technology, Health, MSD, Observational study, IPhone, Biomarker, Merck & Co., Drug development, Translational medicine

Koneksa , a healthcare technology company pioneering evidence-based digital biomarkers, announced that Merck, known as MSD outside of the United States and Canada, has joined its Data Syndication Partnership program for the LEARNS observational study, which seeks to develop digital biomarkers in neurodegenerative disorders from smart phone-based assessments and wearable technologies.

Key Points: 
  • Koneksa , a healthcare technology company pioneering evidence-based digital biomarkers, announced that Merck, known as MSD outside of the United States and Canada, has joined its Data Syndication Partnership program for the LEARNS observational study, which seeks to develop digital biomarkers in neurodegenerative disorders from smart phone-based assessments and wearable technologies.
  • As a member, Merck researchers will have real-time access to data and results from the ongoing study.
  • The high-precision longitudinal data and in-clinic data from the LEARNS study will guide future development of digital biomarkers of disease progression in Parkinson’s disease.
  • Data syndication gives partners immediate and continuous access to data and results as the study progresses, and access to the study dashboard from Koneksa’s proprietary platform for real-time study monitoring, enabling syndication partners to learn from the study as it progresses.

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Retrieved on: 
Martedì, Marzo 19, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Emory University, Antigen, Streptococcus, International Society, HIV, Risk, Global health, Patient, Cohort, Hospital, Merck & Co., Aes, OPA, Epidemiology, Training school (United States), PCV20, Immunoglobulin G, Attenuated vaccine, MRK, Pediatrics, CDC, Vaccination, PPSV23, Community-acquired pneumonia, Food, FDA, PDUFA, Medicine, Vaccine

V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116 in all STRIDE studies presented at the meeting.

Key Points: 
  • V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116 in all STRIDE studies presented at the meeting.
  • If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.
  • Participants were enrolled based on previous pneumococcal vaccination with PPSV23, PCV15, PCV13 (pneumococcal 13-valent conjugate vaccine), PPSV23+PCV13, PCV13+PPSV23 or PCV15+PPSV23, and received either V116, PCV15 or PPSV23.
  • V116 elicited comparable immune responses to the comparator, PCV15+PPSV23, for all 13 shared serotypes and higher immune responses for the eight serotypes covered only by V116.

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Venerdì, Marzo 15, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, MSD, OS, Chemoradiotherapy, CRT, Obstetrics, Congress, Gynaecology, CPS, Survival, Disease, Progression-free survival, Data monitoring committee, Cervical cancer, Patient, Neoplasm, Merck & Co., Overalls, Humanitas University, Bevacizumab, MRK, Cancer, ESMO, PFS, FIGO, PD-L1, Food, Pharmaceutical industry

At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.

Key Points: 
  • At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.
  • The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified.
  • Results will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.
  • As previously reported , KEYNOTE-A18 met its other primary endpoint of progression-free survival (PFS) in 2023.

PENDULUM® Announces the Branding of its Strategic Advisory Services with the Launch of Pendulum Sports & Entertainment

Retrieved on: 
Giovedì, Marzo 14, 2024
Content Marketing, General Sports, Sports, Entertainment, Consulting, Advertising, Communications, Professional Services, General Entertainment, MSD, EPL, Negotiation, Culture, Sport, BDT, Partnership, Branding, LLP, Athlete, MLS, NWSL, MLB, Ecosystem, Partner, Holding, NBA, Family, Reinforcement learning

Pendulum Holdings, LLC (“Pendulum”), a strategic investment and advisory platform, today announced the launch of Pendulum Sports & Entertainment LLC (“PSE”), a dedicated team of senior professionals within Pendulum that provides trusted, strategic advisory services to a formidable generation of brand owners building businesses and partnerships that move and lead culture.

Key Points: 
  • Pendulum Holdings, LLC (“Pendulum”), a strategic investment and advisory platform, today announced the launch of Pendulum Sports & Entertainment LLC (“PSE”), a dedicated team of senior professionals within Pendulum that provides trusted, strategic advisory services to a formidable generation of brand owners building businesses and partnerships that move and lead culture.
  • PSE serves as a transformative bridge between its clients’ brands and their most significant business ambitions and endeavors.
  • Founded in 2019 by D’Rita and Robbie Robinson, Pendulum seeks to reimagine how great companies are built and redefine who gets to build them.
  • “The launch of PSE demonstrates continued momentum in our business and is a significant milestone for Pendulum.

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
Mercoledì, Marzo 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

Pearl Bio Inks Collaboration with Merck to Discover Novel Engineered Biologics

Retrieved on: 
Martedì, Marzo 12, 2024
Biotechnology, FDA, Diabetes, Health, Legal, Pharmaceutical, Professional Services, Oncology, Other Science, Research, Infectious Diseases, General Health, Genetics, Science, MSD, Entrepreneurship, Yale University, Partnership, Synthetic biology, Epitope, Khosla Ventures, Pearl, Merck & Co., Merck, GRO, Cancer, Stanford University, Scottish Register of Tartans, Pharmaceutical industry

Pearl Bio (a synthetic biology company backed by Khosla Ventures) today announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the United States and Canada, to discover biologic therapies comprising non-standard amino acids.

Key Points: 
  • Pearl Bio (a synthetic biology company backed by Khosla Ventures) today announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the United States and Canada, to discover biologic therapies comprising non-standard amino acids.
  • "Merck is excited to collaborate with Pearl, a pioneer in developing recoded organisms, to produce novel biologics enabled by synthetic chemistries,” shared Juan Alvarez, Vice President of Discovery Biologics at Merck Research Laboratories.
  • Backed by Khosla Ventures, Pearl Bio was launched by Scientific Co-Founders Drs.
  • (Pearl Bio) bringing together an exclusive platform technology to advance multi-functionalized biologics and biomaterials by encoding synthetic chemistries.

Merck Completes Acquisition of Harpoon Therapeutics, Inc.

Retrieved on: 
Lunedì, Marzo 11, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, MSD, Glomus tumor, Carcinoma, EPS, BCMA, Patient, Neoplasm, Merck & Co., Acquisition, Cancer, Epithelial cell adhesion molecule, DLL3, MRK, Safety, Pharmacokinetics, B-cell maturation antigen, SCLC, Food, Pharmaceutical industry

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP).

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP).
  • Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be publicly traded or listed on the Nasdaq Stock Market.
  • “We continue to augment and diversify our oncology pipeline with innovative approaches to help people with cancer worldwide,” said Dr. Dean Y. Li, president, Merck Research Laboratories.
  • Under the terms of the merger agreement, Merck, through a subsidiary, has acquired all outstanding shares of Harpoon.

American College of Education Presents Four Full Scholarships in Partnership With Indiana Association of Public Education Foundation

Retrieved on: 
Mercoledì, Marzo 27, 2024
MSD, Tippecanoe School Corporation, Partnership, Education, Lake Central School Corporation, Organization, American College, ACE

INDIANAPOLIS, March 27, 2024 /PRNewswire/ -- American College of EducationⓇ (ACE) has announced a partnership with the Indiana Association of Public Education Foundation (INAPEF) to award full tuition scholarships to four education professionals in Indiana representing the MSD of Wayne Township, Tippecanoe School Corporation, Center Grove Community School Corporation and Lake Central School Corporation. The recipients will receive what amounts to $25K worth of scholarship funding for the 2023-24 school year.

Key Points: 
  • INDIANAPOLIS, March 27, 2024 /PRNewswire/ -- American College of EducationⓇ ( ACE ) has announced a partnership with the Indiana Association of Public Education Foundation (INAPEF) to award full tuition scholarships to four education professionals in Indiana representing the MSD of Wayne Township, Tippecanoe School Corporation, Center Grove Community School Corporation and Lake Central School Corporation.
  • The recipients will receive what amounts to $25K worth of scholarship funding for the 2023-24 school year.
  • Both organizations aim to use the scholarships to support INAPEF member organizations and ACE's mission of providing access to affordable, flexible and high-quality education.
  • "This collaboration is a great way to support educator development in Indiana," INAPEF Association Administrator Krista Baber added.

Josh Harris & David Blitzer Launch Unrivaled Sports And Take Significant, Strategic Investment From The Chernin Group

Retrieved on: 
Mercoledì, Marzo 27, 2024
MSD, Friends, Nike (company), Peter Chernin, Sport, Learning, BDT, Philosophy, Partnership, Baseball, SpringHill Company, TCG (company), Growth, Athlete, Blitzer, Campion, LA28, Real Salt Lake, Investment, Baseball Factory, Paralympic Games, TCG, Family, UCLA, Olympic Gold, Hall

NEW YORK, March 27, 2024 /PRNewswire/ -- Josh Harris and David Blitzer announced today the formation of Unrivaled Sports, the new parent company for their growing portfolio of youth sports properties. As part of the announcement, The Chernin Group ("TCG"), a multi-stage investment firm dedicated to building consumer businesses, completed a significant strategic investment in Unrivaled Sports. Andy Campion, former Chief Operating Officer of Nike, Inc. and long-time Disney executive, has been named Unrivaled Sports' Chairman of the Board. Through its 12 owned and operated facilities, Unrivaled Sports welcomes more than 550,000 athletes and 1.1 million attendees annually.

Key Points: 
  • As part of the announcement, The Chernin Group ("TCG"), a multi-stage investment firm dedicated to building consumer businesses, completed a significant strategic investment in Unrivaled Sports.
  • Andy Campion, former Chief Operating Officer of Nike, Inc. and long-time Disney executive, has been named Unrivaled Sports' Chairman of the Board.
  • Through its 12 owned and operated facilities, Unrivaled Sports welcomes more than 550,000 athletes and 1.1 million attendees annually.
  • "Through Unrivaled Sports, we're not just investing in sports; we're investing in future generations by making sports more inclusive and accessible in communities across the nation," Harris said.

FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform

Retrieved on: 
Venerdì, Marzo 15, 2024
MSD, Health, Growth, Pig, Merck, Behavior, MRK, Schering-Plough, HOD, Merck & Co., Animal, Artificial intelligence

HOD HASHARON, Israel, March 15, 2024 /PRNewswire/ -- FarmSee, a pioneer in camera-based Artificial Intelligence ("AI") solutions for swine monitoring and production optimization, is excited to announce a strategic collaboration with MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK).  MSD Animal Health, a biopharmaceuticals and technology solutions company, has participated in FarmSee's A round and has entered into a long-term agreement to integrate FarmSee's AI- based weighing technology into its global offerings for swine producers. FarmSee also has partnered with Munters (STO:MTRS) in their A round funding.

Key Points: 
  • FarmSee also has partnered with Munters (STO:MTRS) in their A round funding.
  • FarmSee's Initial focus is on continuous individual weight monitoring, which is critical for tracking the animals' growth pattern.
  • "This collaboration not only validates the value of our technology but also opens new opportunities for growth and expansion for FarmSee.
  • We look forward to the growth and development of FarmSee's swine-monitoring technology, which will integrate into our suite of identification, monitoring and traceability animal health solutions.